Parasitic helminths and protozoa: Treasure boxes of disease modifying anti-rheumatic drugs

被引:0
|
作者
Osada, Yoshio [1 ]
Shimizu, Shoichi [1 ]
Morita, Kentaro [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Immunol & Parasitol, 1-1 Iseigaoka,Yahatanishi Ku, Kitakyushu 8078555, Japan
关键词
Parasite; Helminth; Protozoa; Immunomodulation; Schistosoma; Trichinella; Plasmodium; DMARD; Th17; Cytokine; Microbiota; Collagen; Adjuvant; COLLAGEN-INDUCED ARTHRITIS; SCHISTOSOMA-MANSONI INFECTION; AMELIORATES JOINT DISEASE; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ARTHRITIS; ADJUVANT ARTHRITIS; BONE EROSION; TNF-ALPHA; B-CELLS;
D O I
10.1016/j.parint.2024.103000
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Parasites generally survive in their hosts by employing various immunomodulation and immune evasion mechanisms. "helminth therapy" is one strategy that harnesses these parasite-specific beneficial properties for the therapeutic treatment of autoimmune and allergic diseases. Although numerous experimental reports have documented the anti-autoimmune activities of parasitic infections and parasite-derived products, the underlying mechanisms remain insufficiently elucidated due to the significant diversity among parasite species and auto- immune conditions. Rheumatoid arthritis (RA) is one of the most prevalent autoimmune disorders, presenting a substantial opportunity for the therapeutic use of parasites as novel disease-modifying antirheumatic drugs (DMARDs). In this paper, we summarize the immunomodulatory properties of parasites, focusing on their anti- arthritic mechanisms, and discuss the potential of parasite-derived products for the treatment of RA.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] TUBERCULOSIS RISK IN CHILDREN WITH RHEUMATIC DISEASES TREATED WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Kavadichanda, C.
    Ajmani, S.
    Maccora, I.
    Balan, S.
    Ramanan, A.
    Agarwal, V.
    Gupta, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1784 - 1785
  • [22] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [23] The use of conventional disease-modifying anti-rheumatic drugs in established RA
    Jurgens, M. S.
    Jacobs, J. W. G.
    Bijlsma, J. W. J.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2011, 25 (04): : 523 - 533
  • [24] PATIENTS' BELIEFS RELATING TO THE USE AND EFFICACY OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Goodacre, L. J.
    Smith, J.
    Goodacre, J. A.
    RHEUMATOLOGY, 2002, 41 : 73 - 73
  • [25] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [26] Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice
    Grove, ML
    Hassell, AB
    Hay, EM
    Shadforth, MF
    QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2001, 94 (06): : 309 - 319
  • [27] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [28] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [29] Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
    Ingrid Nota
    Constance H. C. Drossaert
    Erik Taal
    Harald E. Vonkeman
    Cees J. Haagsma
    Mart A. F. J. van de Laar
    Arthritis Research & Therapy, 18
  • [30] Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
    Nota, Ingrid
    Drossaert, Constance H. C.
    Taal, Erik
    Vonkeman, Harald E.
    Haagsma, Cees J.
    van de Laar, Mart A. F. J.
    ARTHRITIS RESEARCH & THERAPY, 2016, 18